- Using AstraZeneca's playbook, Zoetis (NYSE:ZTS -0.3%) presents its plan to drive growth and create shareholder value in its first Investor Day event.
- Three capabilities will drive growth: the firm's direct selling model, its customer-focused R&D and its robust high-quality supply chain.
- 2015 Guidance: Revenues: $4.85B - 4.95B (6.5 - 8.5% operational growth); GAAP EPS: $1.36 - 1.43; non-GAAP EPS: $1.61 - 1.68.
- Valeant should not expect a bargain if it decides to make a bid.
- Previously: Zoetis could be fallback option for Valeant